TB-500
Tissue repair / recovery
Status & caution. Not FDA-approved. Among the 12 peptides removed from Category 2 in April 2026 and scheduled for PCAC review on 23 July 2026; compounding is not authorised pending a favourable vote and FDA rulemaking. Pro-angiogenic and pro-migratory in models; like BPC-157, human evidence is minimal. Banned in sport (WADA).
At a glance
Indications & what it's studied for
Reported for muscle/tendon recovery, flexibility, and wound healing via actin regulation and angiogenesis.
Contraindications & cautions
Caution with active or prior cancer given pro-angiogenic effects; no human-use labelling exists.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community protocols often describe a higher 'loading' phase tapering to maintenance, subcutaneously; unvalidated in humans.
Routes of administration
Subcutaneous (sometimes intramuscular) injection.
Don't combine with
No well-defined interactions; grey-market purity is the main hazard.
Reported to stack with
Paired with BPC-157 for healing ('Wolverine stack').
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Thymosin β4 has genuine cell-biology literature (cardiac and corneal repair models); the marketed 'TB-500' shortcut lacks controlled human trials.
Before acting on anything here, see Safety & the grey market and how to read a COA.